Last deal

$150M

Amount

Series E

Stage

25.05.2023

Date

3

all rounds

$224.85M

Total amount

date founded

Financing round

General

About Company
Carmot Therapeutics is a biotechnology company that develops disease-modifying therapies for metabolic diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2008

Number of employees

Company Type

For Profit

Last funding type

Series E

IPO status

Private

Description

Founded in 2008 and based in Berkeley, California, Carmot Therapeutics utilizes its Chemotype Evolution technology to identify new therapeutic targets and rapidly discover drugs for metabolic diseases, cancer, and inflammation. Their focus is on treating inflammatory, metabolic, and neurological diseases by addressing the root causes and speeding up the discovery of disease-modifying therapies.
Contacts
Similar Companies
1000
IMTherapeutics

IMTherapeutics

IM Therapeutics develops personalized immuno-therapeutic drugs for autoimmune diseases based on HLA genes.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Aurora, CO, USA

total rounds

1

total raised

$10M
IHP Therapeutics

IHP Therapeutics

IHP Therapeutics develops novel glycan therapeutics for cancer and hemolytic diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care
EraCal

EraCal

EraCal Therapeutics develops cutting-edge drugs to treat diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Zürich, Switzerland

total rounds

5

total raised

$1.14M
Kyverna Therapeutics

Kyverna Therapeutics

Kyverna Therapeutics is a company that is developing new therapies and cures for serious autoimmune diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Berkeley, CA, USA

total rounds

3

total raised

$170M
M&A Details
1

Transaction name

Acquired by

Roche

announced date

04.12.2023

price

$2.7B

Financials

Funding Rounds
7
3

Number of Funding Rounds

$224.85M

Money Raised

Their latest funding was raised on 25.05.2023. Their latest investor Millennium Management. Their latest round Series E

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Deep Track Capital

Deep Track Capital

Deep Track Capital is a Greenwich-based investment firm focused on life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Greenwich, CT, USA

count Of Investments

60

count Of Exists

1
Amgen Ventures

Amgen Ventures

Amgen Ventures is a biotech-focused venture capital firm.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

count Of Investments

73

count Of Exists

10
Horizons Ventures

Horizons Ventures

Horizons Ventures is a Hong Kong-based venture capital firm that invests in disruptive and technology-focused start-ups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Hong Kong Island, Hong Kong

count Of Investments

284

count Of Exists

34
The Column Group

The Column Group

The Column Group is a venture capital firm focused on creating the next generation of biotechnology companies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

count Of Investments

95

count Of Exists

8
Co-Investors
Investors
15
5

Number of lead investors

15

Number of investors

Investor 
Lead 
Round 
Partners 
Millennium Management

Millennium Management

Millennium is a global alternative investment management firm founded in 1989.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Consulting

count Of Investments

15

count Of Exists

1
RA Capital Management

RA Capital Management

RA Capital Management is a Boston-based investment advisor that specializes in the life-sciences and drug development sectors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Health Care, Financial Services

Location

Boston, MA, USA

count Of Investments

381

count Of Exists

33
Derek DiRocco

Derek DiRocco

Derek DiRocco is a Principal on the Investment Team at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Ltd. Previously, Derek covered solid tumor oncology landscapes. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

current job

RA Capital Management
RA Capital Management
Frazier Life Sciences

Frazier Life Sciences

Frazier Life Sciences invests in and builds companies developing novel therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Life Science

Location

Seattle, WA, USA

count Of Investments

31

count Of Exists

1

People

Founders
2

Stig K. Hansen

Stig K. Hansen is a Founder & CEO at Carmot Therapeutics.

current job

Carmot Therapeutics
Carmot Therapeutics

organization founded

1

Stig K. Hansen

Daniel A. Erlanson

Daniel Erlanson is VP of Chemistry at Frontier Medicines.

current job

Frontier Medicines
Frontier Medicines

organization founded

1

Daniel A. Erlanson

Employee Profiles
3
Aetna Wun Trombley

Aetna Wun Trombley

Board Director

Stig K. Hansen

Founder & CEO

Activity

Recent News
9
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month